Seismic Therapeutic vs Synkrino Biotherapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (36 vs 35)
Seismic Therapeutic logo

Seismic Therapeutic

EmergingLife Sciences & BioTech

AI-Driven Immunology Drug Discovery

Seismic Therapeutic raised $222M+ total ($121M Series B in 2023, $25M in 2025) using its IMPACT ML platform; dosed first patient in Phase 1 for S-4321 bifunctional antibody in autoimmune disease.

AI VisibilityBeta
Overall Score
D36
Category Rank
#100 of 198
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
32
Gemini
33

About

Seismic Therapeutic is a clinical-stage biotechnology company based in Boston, Massachusetts that applies machine learning to the discovery and development of novel immunotherapies for autoimmune diseases. Founded with a focus on precision immunology, Seismic built its IMPACT platform to model the complex biology of adaptive immunity — identifying which immune cell populations drive specific autoimmune conditions and designing biologics that precisely modulate those populations without broadly suppressing the immune system. This targeted approach aims to produce safer, more effective treatments for conditions like lupus, rheumatoid arthritis, and inflammatory bowel disease.

Full profile
Synkrino Biotherapeutics logo

Synkrino Biotherapeutics

EmergingLife Sciences & BioTech

AI-Driven Immunology Drug Discovery

Synkrino Biotherapeutics uses its AI and Immunology Discovery Engine (AIDE) to identify novel drug targets from immune patient tissue data; targets immune-mediated and inflammatory diseases; early-stage Oakland, CA biotech.

AI VisibilityBeta
Overall Score
D35
Category Rank
#129 of 198
AI Consensus
86%
Trend
stable
Per Platform
ChatGPT
34
Perplexity
39
Gemini
37

About

Synkrino Biotherapeutics is an Oakland, California-based biotechnology company applying artificial intelligence and multiomics analysis to drug discovery in immune-mediated and inflammatory diseases. Its core proprietary platform, the AI and Immunology Discovery Engine (AIDE), integrates high-dimensional immune tissue data from patients — including single-cell RNA sequencing, spatial transcriptomics, and proteomics — with machine learning models to identify novel, biologically validated drug targets that emerge from the real immunological complexity of human disease rather than simplified preclinical models.

Full profile

AI Visibility Head-to-Head

36
Overall Score
35
#100
Category Rank
#129
76
AI Consensus
86
stable
Trend
stable
39
ChatGPT
34
32
Perplexity
39
33
Gemini
37
40
Claude
39
32
Grok
39

Key Details

Category
AI-Driven Immunology Drug Discovery
AI-Driven Immunology Drug Discovery
Tier
Emerging
Emerging
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.